Skip to main content
. Author manuscript; available in PMC: 2021 Jan 30.
Published in final edited form as: J Pharm Biomed Anal. 2019 Sep 30;178:112884. doi: 10.1016/j.jpba.2019.112884

Figure 11. Effects of Caudal Fourth Ventricular (CV4) Administration of the ERα Antagonist 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride (MPP) or ERβ Antagonist 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP) Ventromedial Hypothalamic Nucleus (VMN) Glycogen Metabolic Enzyme Protein Expression during Insulin-Induced Hypoglycemia (IIH) in Female Versus Male Rats.

Figure 11.

Micropunch-dissected VMN tissue was obtained from groups of male and estradiol – implanted ovariectomized female rats pretreated by CV4 administration of MPP, PHTPP, or vehicle prior to sc insulin (INS) injection for Western blot analysis of glycogen synthase (GS) [Panel A, male; Panel B, female] or glycogen phosphorylase-muscle type (GPmm) [Panel C, male; Panel D, female]. Data depict mean normalized protein optical density (O.D.) values ± S.E.M. for vehicle-pretreated animals injected sc with vehicle- (white bars; n=6) or INS (gray bars; n=6) or INS-injected rats pretreated with MPP (cyan bars; n=6) or PHTPP (purple gray bars; n=6). *p<0.05; **p<0.01; **p<0.001.